Clinical outcomes and patient-reported outcomes after oncoplastic breast surgery in breast cancer patients : A matched cohort study
Copyright © 2024, the Chinese Medical Association..
BACKGROUND: Surgery is the recommended treatment for breast cancer, the most common cancer in women in Taiwan and the leading cause of cancer-related deaths. Although breast-conserving surgery (BCS) has good prognosis, in some cases, BCS may cause more significant deformities and interfere with the patient's psychosocial well-being. Oncoplastic breast surgery (OBS) is the treatment option in these cases. This study aimed to determine the outcomes of OBS and BCS regardless of clinical and patient-reported esthetic outcomes.
METHODS: Between 2015 and 2020, 50 patients who underwent OBS at our hospital after complete treatment were enrolled. With 1:2 matched ratios, 100 patients were enrolled in the BCS control group. Clinical outcomes were analyzed. The BREAST-Q questionnaire was then assessed 6 months after the completion of treatment for subjective patient-reported outcomes.
RESULTS: Due to the matching process, no difference was noted between the two groups in terms of demographic data such as age, comorbidities, or tumor characteristics. There were no significant differences in the local recurrence rate, disease-free survival, overall survival, positive margin rate, rewide excision rate, conversion to mastectomy rate, or complication rate (major or minor) between both groups. However, the OBS group showed higher satisfaction with breasts in the BREAST-Q questionnaire ( p < 0.001). The mean follow-up time was 38.77 ± 14.70 months in the BCS group and 29.59 ± 14.06 months in the OBS group.
CONCLUSION: OBS seems to be a safe and feasible surgery in breast cancer patients because clinical outcomes are compatible with BCS. Moreover, the OBS group had better patient-reported outcomes in terms of satisfaction.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:87 |
|---|---|
| Enthalten in: |
Journal of the Chinese Medical Association : JCMA - 87(2024), 3 vom: 01. März, Seite 320-327 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chou, Hsuan-Yu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 06.03.2024 Date Revised 06.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1097/JCMA.0000000000001055 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36742990X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36742990X | ||
| 003 | DE-627 | ||
| 005 | 20240306232739.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240123s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/JCMA.0000000000001055 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1318.xml |
| 035 | |a (DE-627)NLM36742990X | ||
| 035 | |a (NLM)38252489 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chou, Hsuan-Yu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical outcomes and patient-reported outcomes after oncoplastic breast surgery in breast cancer patients |b A matched cohort study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.03.2024 | ||
| 500 | |a Date Revised 06.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024, the Chinese Medical Association. | ||
| 520 | |a BACKGROUND: Surgery is the recommended treatment for breast cancer, the most common cancer in women in Taiwan and the leading cause of cancer-related deaths. Although breast-conserving surgery (BCS) has good prognosis, in some cases, BCS may cause more significant deformities and interfere with the patient's psychosocial well-being. Oncoplastic breast surgery (OBS) is the treatment option in these cases. This study aimed to determine the outcomes of OBS and BCS regardless of clinical and patient-reported esthetic outcomes | ||
| 520 | |a METHODS: Between 2015 and 2020, 50 patients who underwent OBS at our hospital after complete treatment were enrolled. With 1:2 matched ratios, 100 patients were enrolled in the BCS control group. Clinical outcomes were analyzed. The BREAST-Q questionnaire was then assessed 6 months after the completion of treatment for subjective patient-reported outcomes | ||
| 520 | |a RESULTS: Due to the matching process, no difference was noted between the two groups in terms of demographic data such as age, comorbidities, or tumor characteristics. There were no significant differences in the local recurrence rate, disease-free survival, overall survival, positive margin rate, rewide excision rate, conversion to mastectomy rate, or complication rate (major or minor) between both groups. However, the OBS group showed higher satisfaction with breasts in the BREAST-Q questionnaire ( p < 0.001). The mean follow-up time was 38.77 ± 14.70 months in the BCS group and 29.59 ± 14.06 months in the OBS group | ||
| 520 | |a CONCLUSION: OBS seems to be a safe and feasible surgery in breast cancer patients because clinical outcomes are compatible with BCS. Moreover, the OBS group had better patient-reported outcomes in terms of satisfaction | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Tseng, Ling-Ming |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Hsu |e verfasserin |4 aut | |
| 700 | 1 | |a Perng, Cherng-Kang |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Chi-Cheng |e verfasserin |4 aut | |
| 700 | 1 | |a Tsai, Yi-Fang |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Yen-Shu |e verfasserin |4 aut | |
| 700 | 1 | |a Lien, Pei-Ju |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Chin-Jung |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the Chinese Medical Association : JCMA |d 2003 |g 87(2024), 3 vom: 01. März, Seite 320-327 |w (DE-627)NLM124866131 |x 1728-7731 |7 nnns |
| 773 | 1 | 8 | |g volume:87 |g year:2024 |g number:3 |g day:01 |g month:03 |g pages:320-327 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/JCMA.0000000000001055 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 87 |j 2024 |e 3 |b 01 |c 03 |h 320-327 | ||